|
|
Blood, 1 October 2007, Vol. 110, No. 7, pp. 2342-2350.
Prepublished online as a Blood First Edition Paper on May 21, 2007September 14, 2007; DOI 10.1182/blood-2007-01-065573.
 Previous Article | Next Article 
Submitted January 3, 2007
Accepted May 10, 2007
Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV( 51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene
Apollina Goel, Stephanie K. Carlson, Kelly L. Classic, Suzanne Greiner, Shruthi Naik, Anthony T. Power, John C. Bell, and Stephen J. Russell*
Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN, United States
Division of Radiation Oncology, Dept of Radiology, Mayo Clinic College of Medicine, Rochester, MN, United States
Section of Safety, Mayo Clinic College of Medicine, Rochester, MN, United States
Ottawa Health Research Insitute, University of Ottawa, Ottawa, Canada
* Corresponding author; email: sjr{at}mayo.edu.
Multiple myeloma is a radiosensitive malignancy that is currently incurable. Here, we generated a novel recombinant vesicular stomatitis virus [VSV( 51)-NIS] that has a deletion of methionine 51 in the matrix protein and expresses the human sodium iodide symporter (NIS) gene. VSV(51)-NIS showed specific oncolytic activity against myeloma cell lines and primary myeloma cells and was able to replicate to high titers in myeloma cells in vitro. Iodide uptake assays showed accumulation of radioactive iodide in VSV(51)-NIS-infected myeloma cells that was specific to the function of the NIS transgene. In bg/nd/xid mice with established subcutaneous myeloma tumors, administration of VSV(51)-NIS resulted in high intratumoral virus replication and tumor regression. VSV-associated neurotoxicity was not observed. Intratumoral spread of the infection was monitored non-invasively by serial gamma camera imaging of 123I-iodide biodistribution. Dosimetry calculations based on these images pointed to the feasibility of combination radiovirotherapy with VSV(51)-NIS plus 131I. Immunocompetent mice with syngeneic 5TGM1 myeloma tumors (either subcutaneous or orthotopic) showed significant enhancements of tumor regression and survival when VSV(51)-NIS was combined with 131I. These results show that VSV(51)-NIS is a safe oncolytic agent with significant therapeutic potential in multiple myeloma.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. Peerlinck, A. Merron, P. Baril, S. Conchon, P. Martin-Duque, C. Hindorf, J. Burnet, M. Quintanilla, M. Hingorani, R. Iggo, et al.
Targeted Radionuclide Therapy Using a Wnt-Targeted Replicating Adenovirus Encoding the Na/I Symporter
Clin. Cancer Res.,
November 1, 2009;
15(21):
6595 - 6601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Klutz, V. Russ, M. J. Willhauck, N. Wunderlich, C. Zach, F. J. Gildehaus, B. Goke, E. Wagner, M. Ogris, and C. Spitzweg
Targeted Radioiodine Therapy of Neuroblastoma Tumors following Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene
Clin. Cancer Res.,
October 1, 2009;
15(19):
6079 - 6086.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hakkarainen, M. Rajecki, M. Sarparanta, M. Tenhunen, A. J. Airaksinen, R. A. Desmond, K. Kairemo, and A. Hemminki
Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter
Clin. Cancer Res.,
September 1, 2009;
15(17):
5396 - 5403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
